Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free TVTX Stock Alerts $5.26 -0.13 (-2.41%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Travere Therapeutics Short Interest DataCurrent Short Volume11,800,000 sharesPrevious Short Volume10,600,000 sharesChange Vs. Previous Month+11.32%Dollar Volume Sold Short$74.58 millionShort Interest Ratio / Days to Cover9.9Last Record DateApril 15, 2024Outstanding Shares76,109,000 sharesPercentage of Shares Shorted15.50%Today's Trading Volume1,220,034 sharesAverage Trading Volume1,268,295 sharesToday's Volume Vs. Average96% Short Selling Travere Therapeutics ? Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTVTX Short Interest Over TimeTVTX Days to Cover Over TimeTVTX Percentage of Float Shorted Over Time Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Travere Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32 3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71 3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49 2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56 2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74 1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93 Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53 12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99 12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66 11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28 11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17 10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48 10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10 9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94 9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69 8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28 8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20 7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19 7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31 6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36 6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20 5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89 5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34 4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57 4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32 3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49 3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27 2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16 2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12 1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40 1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32 12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03 12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50 11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13 11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51 10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68 10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68 9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64 9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20 8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. TVTX Short Interest - Frequently Asked Questions What is Travere Therapeutics' current short interest? Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 11,800,000 shares of TVTX short. Learn More on Travere Therapeutics' current short interest. What is a good short interest ratio for Travere Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 10.0. Learn More on Travere Therapeutics's short interest ratio. Which institutional investors are shorting Travere Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Capstone Investment Advisors LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Travere Therapeutics' short interest increasing or decreasing? Travere Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 11,800,000 shares, an increase of 11.3% from the previous total of 10,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Travere Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Travere Therapeutics: Entrada Therapeutics, Inc. (9.71%), Theravance Biopharma, Inc. (14.72%), Shattuck Labs, Inc. (4.42%), Avid Bioservices, Inc. (16.32%), Acelyrin, Inc. (12.80%), Lexicon Pharmaceuticals, Inc. (8.17%), IGM Biosciences, Inc. (25.04%), Adlai Nortye Ltd. (0.02%), Fulcrum Therapeutics, Inc. (4.07%), Larimar Therapeutics, Inc. (5.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Travere Therapeutics stock? Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Travere Therapeutics? A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further. How often is Travere Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Entrada Therapeutics Short Interest Data Theravance Biopharma Short Interest Data Shattuck Labs Short Interest Data Avid Bioservices Short Interest Data Acelyrin Short Interest Data Lexicon Pharmaceuticals Short Interest Data IGM Biosciences Short Interest Data Adlai Nortye Short Interest Data Fulcrum Therapeutics Short Interest Data Larimar Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TVTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics